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Abstract
Background
The Neuberger review made a number of recommendations to improve end of life care,
including research into the biology of dying. An important aspect of the biology of dying is
the identification of biomarkers as indices of disease processes. Biomarkers have the poten-
tial to inform the current, limited understanding of the dying process and assist clinicians in
recognising dying, in particular how to distinguish dying from reversible acute deterioration.
Objectives
To critically appraise the literature on biological factors that may be used as prognostic indi-
cators in advanced cancer patients and to identify candidate biomarkers of the dying pro-
cess that can be measured serially in cancer patients’ bodily fluids.
Methods
A systematically structured review was conducted using three electronic databases. A hand
search of six peer-reviewed journals and conference abstracts was also conducted. Studies
reporting prognostic biomarkers in cancer patients with a median survival of90 days and
post-mortem studies were included. Final levels of evidence and recommendations were
made using the Evidence Based Medicine modified GRADE system.
Results
30 articles were included. Seven prognostic biological factors demonstrated Grade A evi-
dence (lymphocyte count, white blood cell count, serum C-reactive protein, albumin,
sodium, urea and alkaline phosphatase). An additional eleven prognostic factors were iden-
tified with Grade B evidence (platelet count, international normalised ratio, serum vitamin
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Conclusion
The biology of dying is an important area for future research, with the evidence focused on
signs, symptoms and prognostic factors. This review identifies a number of common themes
shared amongst advanced cancer patients and highlights candidate biomarkers which may
be indicative of a common biological process to dying.
Background
In a comprehensive evaluation of the challenges and actions required to provide the best care
for dying patients, the Neuberger review identified the need for further research into the biol-
ogy of dying as a priority [1]. The biology of dying is an umbrella topic that encompasses the
physiological and biological changes attributed to the dying process, in addition to the aetiol-
ogy of signs and symptoms commonly seen in the last days, weeks and months of life.
There is significant uncertainty in consistently and accurately identifying the dying phase
(last days of life) and no definitive diagnostic criteria exist [1,2]. Little is known about the pro-
cess of dying [1] and in the final days of life, new symptoms or exacerbation or recurrence of
previously well-controlled symptoms can occur [3,4]. A prospective cohort study of 343 doc-
tors found only 20% of prognostic estimates in hospice patients were accurate and that, overall
doctors overestimated survival by a factor of five [5].
It has been extensively documented that cancer patients experience a sharp functional
decline in the last months of life [6]. The prevalence of common terminal symptoms amongst
patients with advanced cancer is suggestive of a common terminal trajectory; historically
termed the “terminal cancer syndrome” [7]. Although the concept of the “terminal cancer syn-
drome” has been largely superseded, there is significant evidence for the prognostic impor-
tance of dyspnoea (Grade B), cancer anorexia-cachexia syndrome (CACS, Grade B), delirium
(Grade B) and low performance status (Grade A) in advanced cancer [8]. A systematic review
by Kehl et al. demonstrated that dyspnoea (56.7%), pain (52.4%), respiratory tract secretions
(51.4%) and confusion (50.1%) were the most prevalent signs and symptoms that occur in the
last two weeks of life [9]. Further, Hui et al. identified 13 signs highly predictive of death within
three days [10,11].
An important aspect of the biology of dying is the identification of biomarkers as indices of
disease processes. Biomarkers have the potential to inform the current, limited understanding
of the process of dying and assist clinicians in recognising dying, in particular how to distin-
guish dying from reversible acute deterioration. In 2005, Maltoni et al. published evidence-
based recommendations for a number of prognostic biological factors in advanced cancer
patients [8]. Subsequently, a number of prognostic models have been developed that incorpo-
rate prognostic biomarkers [12]. No systematic reviews have been conducted that summarise
the evidence for prognostic biomarkers in advanced cancer patients.
In this systematically structured review, the authors summarise the evidence for prognostic
biomarkers in advanced cancer patients in the last months of life and extrapolate which biolog-
ical processes are affected.
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aminotransferase; AST, aspartate transaminase;
AUC, area under the curve; B12, vitamin B12; BCI,
B12 CRP index; BUN, blood urea nitrogen; CACS,
cancer anorexia-cachexia syndrome; CAR, CRP/
albumin ratio; CPS, Clinicians’ Prediction of
Survival; CRP, C-reactive protein; D-PAP, Delirium-
Palliative Prognostic Score; ECOG PS, Eastern
Cooperative Oncology Group Performance Status;
ESR, erythrocyte sedimentation rate; GC-MS, Gas
Chromatography Mass Spectrometry; GGT,
gamma-glutamyl transpeptidase; GPS, Glasgow
Prognostic Score; IFNγ, interferon gamma; IL-10,
interleukin-10; IL-12(p70), interleukin-12(p70); IL-
18, interleukin-18; IL-1ra, interleukin-1 receptor
antagonist; IL-1β, interleurkin-1 beta; IL-2,
interleukin-2; IL-4, interleukin-4; IL-6, interleukin-6;
IL-8, interleukin-8; INR, international normalised
ratio; JPOS-PI, Japan Palliative Oncology Study-
Prognostic Index; KPS, Karnofsky Performance
Status; LDH, lactate dehydrogenase; LIF, leukaemia
inhibiting factor; MCP-1, monocyte
chemoattractant protein-1; m-GPS, modified
Glasgow Prognostic Score; MIF, macrophage
migration inhibitory factor; MIP-1α, macrophage
inflammatory protein-1α; MSSE, mini mental state
examination; new-ChPS, new-Chinese Advanced
Cancer Patients Scale; NLR, neutrophil-lymphocyte
ratio; NMR, Nuclear Magnetic Resonance
Spectrometry; NPV, negative predictive value; PaP
Score, Palliative Prognostic Score; PINI, Prognostic
Inflammatory and Nutritional Index; PiPS,
Prognosis in Palliative Care Study; PiPS-A,
modified Prognosis in Palliative Care Study-A;
PiPS-B, modified Prognosis in Palliative Care
Study-B; PPI, Palliative Performance Index; PPV,
positive predictive value; PTH, parathyroid
hormone; PTHrP, parathyroid hormone related
protein; RNA, ribonucleic acid; sTNF- r1, soluble
tumour necrosis factor receptor 1; TGF-β1,
transforming growth factor β1; TNFα, tumour
necrosis factor alpha; TTD, time from initial
diagnosis to diagnosis of terminal disease; VOCs,
volatile organic compounds; WBC, white blood cell
count; WPBAL, WBC/platelet/BUN/AST/LDH
prognostic score; WPCBAL, WBC/platelet/CRP/
BUN/AST/LDH prognostic score.
Objectives
This systematically structured review was conducted to collate and critically appraise the litera-
ture on prognostic biomarkers in advanced cancer. The following questions formed the basis
of this review:
1. What biological factors are prognostic in advanced cancer patients in the last days, weeks or
months of life?
2. Can serial measurement of identified biomarkers detect the last days to weeks of life in
advanced cancer patients?
Methods
Given that no randomised controlled trials have been conducted on this research topic, a sys-
tematically structured review was conducted to ensure a replicable and systematic synthesis of
the evidence. The review was structured according to the PRISMA standards for conducting a
systematic review [13].
Literature search methods
On 5th February 2016, three electronic databases were searched (Medline, Scopus and
Cochrane Database of Systematic Reviews) using combinations of the key words, described in
Table 1. Limits were set to humans, adults (aged over 18 years of age) and publication between
1st January 2000 and 5th February 2016. Only published articles were sought. Two reviewers
(VLR and SC) independently searched all designated databases for abstracts and titles. Agree-
ment on inclusion was made by consensus. Additional articles were identified through a hand
search of contents pages of the most recent issues (December 2014 to February 2016) of six rel-
evant peer-reviewed Palliative Medicine journals: Cancer, BMJ Supportive and Palliative Care,
Palliative Medicine, Journal of Palliative Care, Journal of Palliative Medicine, and Journal of
Pain and SymptomManagement. Grey literature was searched through citation tracking and
conference abstracts from the European Association of Palliative Care World Congress 2016,
European Association of Palliative Care World Congress 2015, the Marie Curie Research Con-
ference 2015, the Arts and Science of Hospice Care Annual Conference 2015, the 5th Interna-
tional Conference on Advance Care Planning and End of Life Care 2015, and the International
Congress of Palliative Care 2014. The last literature search was conducted on 16th June 2016.
Institutional review board approval was not sought or required for this literature review.




#1 death OR dying OR terminal care OR terminal illness OR “terminally ill” OR hospice* OR
palliative care
#2 biolog* OR physiolog* OR pathophysiolog* OR patholog* OR biomarker* OR biologic
marker* OR biological marker* OR biological factor* OR “biology of dying” OR prognostic*
OR prognosis OR predict OR mortality OR “terminal cancer syndrome” OR “common
terminal pathway” OR “common terminal trajectory” OR “final common pathway” OR
“terminal syndrome”
#3 cancer OR tumor* OR tumour* OR neoplas* OR oncolog* OR carcinoma
#4 #1 AND #2 AND #3
#5 Limit #4 to humans, all adults (19 years plus), publication year 2000—current
*Truncation
https://doi.org/10.1371/journal.pone.0175123.t001
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Eligibility criteria
The primary objective was the identification of prognostic biomarkers in advanced cancer
patients in the last days, weeks or months of life. Biomarkers were defined as objective, quanti-
fiable characteristics of biological processes [14] quantifiable in bodily fluids and tissues. Given
that most cancer patients seem to follow a common terminal trajectory, [6] only patients with
cancer were included in this study.
Diagnosing imminent death is often difficult and imprecise [1] and terminal physiological
changes are often seen many weeks before death. Further, the definition of “advanced cancer”
is often lacking in the literature. In line with the study by Maltoni et al. this review included
only study populations with a median survival of90 days [8] that, for the purpose of this
study, defines the term “advanced cancer.” This criterion enabled us to capture biological fac-
tors predictive of dying over days, weeks and months of life. Post-mortem studies of cancer
patients specifically looking at biomarkers of the dying process were also included.
All types of peer-reviewed evidence were included and a 16-year timeframe was selected to
ensure comprehensive yet current coverage of the literature, and build on the excellent review
published in 2005 by Maltoni et al (last literature search conducted in 2003).
Articles were excluded if they described only signs, symptoms or physiological changes
associated with imminent death. The following types of articles were also excluded: duplicates,
non-English language, paediatric populations, editorials, commentaries, case reports, reviews
and animal studies. The systematic review by Maltoni et al. was included as it provided an evi-
dence-based summary of the literature up until 2005 [8]. Primary researchers were contacted
by email, where necessary, to clarify information to ensure strict adherence to the inclusion
criteria. Where survival data could not be confirmed, studies were excluded.
Study selection
A review protocol was developed by VLR in advance of the literature search (S2 File). VLR
extracted the data from the studies and discussed the results with SC. Disagreements between
reviewers were resolved by consensus. Reviewers were not blinded for authors, institutions, or
journals of publication. The Liverpool Reviews and Implementation Group (LRiG) at Univer-
sity of Liverpool reviewed and agreed on the employed methodology.
Quality assessment
The primary authors (VLR and SC) used the UK National Institute for Health and Clinical
Excellence (NICE) hierarchy of evidence to assign a quality rating to the potential articles for
inclusion [15]. Given that a variety of research outputs were considered in this review, a critical
appraisal tool described by Hawker et al. [16] was utilised to further evaluate the quality of
studies. Briefly, a four-point scale from one (very poor) to four (good) was assigned to nine
areas including: abstract and title, introduction and aims, methods and data, sampling, data
analysis, ethics and bias, results, transferability/generalisability, and implications and useful-
ness with a total number between 9–36 assigned to each study [16]. The Maltoni et al. seven-
point checklist of quality criteria for evaluation of studies on prognostic factors was also uti-
lised, where one point is assigned to seven criteria including; prospective study design; well-
defined cohort of patients assembled at a common point in the course of their disease; random
patient selection, percentage of patients lost to follow-up20%; ratio between the number of
events (death) and the number of potential predictors 10; prognostic variables fully defined,
accurately measured, and available for all or a high proportion of patients; and reliable mea-
surement of outcome (date of death) [8]. A total score between 1–7 was assigned and high
quality (or low probability of bias) was attributed to studies fulfilling at least five of the seven
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criteria [8]. VLR and SC assessed the quality of potential articles for inclusion independently
and mean scores were assigned. Spearman’s rank correlation coefficient was used to measure
rank correlations of scores between assessors. Data was analyzed using Statistical Software
Package for the Social Sciences1 (SPSS1 version 22.0; IBM SPSS Inc., Chicago, IL). Final lev-
els of evidence and recommendations were made using the Evidence Based Medicine modified
Grading of Recommendations Assessments, Development and Evaluation (GRADE) system
(Grade A = high quality evidence with consistent results, to Grade D = very low quality evi-
dence such as expert opinion) [17].
Results
Study selection
The results of the literature search are summarised in Fig 1. Based on firm application of the
inclusion criteria, 30 articles were included in this systematically structured review (Table 2).
Fig 1. PRISMA flow diagram of this systematically structured review.
https://doi.org/10.1371/journal.pone.0175123.g001
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A selected number of articles were excluded as patient populations had a median survival>90
days. An additional three articles were excluded due to lack of survival data.
Study characteristics
The characteristics of the included studies are summarised in Table 2. A formal meta-analysis
was not conducted because of the heterogeneity of the published studies. A number of studies
utilised univariate rather than multivariate analysis. Both types of studies were included to
ensure a comprehensive summary of the literature. The use of the Evidence Based Medicine
modified GRADE system has highlighted the limitations of univariate analysis for these types
of studies [17].
Table 3 subdivides prognostic biomarkers by grades of evidence. Only five articles inves-
tigated changes in concentrations of identified biomarkers in the last days to weeks of life
(Table 3).
The methodological quality of the included studies ranged between 26–36 using the Hawker
et al. appraisal tool [16]. Using the seven-point checklist of quality criteria, the selected studies
ranged between 3–6 [8]. Spearman’s rank correlation coefficient demonstrated a statistically
significant rank correlation between assessors (rs 1⁄4 0.955 p = 0.000 and rs 1⁄4 0.921 p = 0.000,
respectively). Frequently, sample size calculations were not conducted, and some studies
lacked information about the study setting and patient characteristics. Further, the majority
(97%) of studies had convenience rather than random sampling, a reliable method for identifi-
cation of the date of death was often poor, and a large number of potential prognostic factors
were analysed despite small sample sizes, which meant that the ratio between the number of
deaths and the number of potential prognostic factors frequently scored less than ten.
Discussion
This is the first systematically structured review to evaluate prognostic biomarkers in a hetero-
geneous group of patients with advanced cancer. Seven prognostic biological factors had
Grade A evidence: lymphocyte count, white blood cell (WBC) count, serum albumin, sodium,
C-reactive protein (CRP), urea and alkaline phosphatase (ALP) (Table 3). Few studies have
specifically investigated changes in biomarkers in the last days to weeks of life. In the last two
weeks of life a number of biomarkers were elevated in the blood including: WBC count, plate-
let count, serum CRP, urea, urate, alanine transaminase (ALT), lactate dehydrogenase (LDH),
sodium and plasma interleukin-6 (IL-6). However limitations exist as only five studies specifi-
cally investigated serial measurements of candidate biomarkers in the last weeks of life.
A number of common themes emerged: systemic inflammation, haematological changes,
CACS, hepatic dysfunction, renal dysfunction, and electrolyte changes. A number of biomark-
ers, such as serum albumin could be explained by multiple themes.
Systemic inflammation & haematological changes
There is consistent evidence that the presence of a systemic inflammatory response is associ-
ated with reduced survival in patients with a variety of solid organ tumors [48–50]. Elevated
serum CRP levels are associated with poor prognosis independent of tumour stage [37,51]. IL-
6, interleukin-1 (IL-1) and tumour necrosis factor alpha (TNFα) induce the hepatic synthesis
of CRP. Further, elevated CRP and IL-6 are associated with CACS in advanced cancer [51].
Measurement of serum CRP is readily available and is an ideal biomarker of systemic inflam-
mation. There is Grade A evidence that elevated serum CRP is an independent prognostic fac-
tor in advanced cancer [18,22,29,34,37,42]. Amano et al. demonstrated a clear dose-related
Biomarkers of dying in cancer patients: A systematically structured review
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Table 3. Prognostic biomarkers subdivided by evidence based medicine modified GRADE criteria.
GRADE Quality of Evidence Biomarker
A High • Serum CRPa
• Serum WBCa





B Moderate • Platelet counta
• Serum prealbumin









C Low • Plasma IL-6ab
















D Very Low • Proteinuria
• Serum potassium
• Serum phosphate
ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate transaminase; BUN = blood urea nitrogen; CRP = C-reactive protein; IL-
1ra = interleukin-1 receptor antagonist; IL-1β = interleukin-1 beta; IL-6 = interleukin-6; IL-18 = interleukin-18; ESR = erythrocyte sedimentation rate;
GGT = gamma-glutamyl transferase; INR = international normalised ratio; LDH = lactate dehydrogenase; MCP-1 = monocyte chemoattractant protein-1;
MIF = macrophage migration inhibitory factor; sTNF- r1 = soluble tumour necrosis factor receptor 1; TGF-β1 = transforming growth factor β1;
VOCs = volatile organic compounds; WBC = white blood cell count.
aBiomarkers detectable in the blood in the last two weeks of life
bPrognostic significance not assessed
https://doi.org/10.1371/journal.pone.0175123.t003
Biomarkers of dying in cancer patients: A systematically structured review
PLOS ONE | https://doi.org/10.1371/journal.pone.0175123 April 6, 2017 21 / 31
effect between elevated serum CRP and prognosis, and patients could be divided into four
groups based on CRP concentrations [37] (Table 2).
Only two studies investigated the role of inflammatory cytokines at the end of life
[25,46], this may be because most cytokines have a short plasma half-life and assays are
expensive in relation to serum CRP. Iwase et al. measured changes in plasma levels of vari-
ous cytokines in 28 terminally ill cancer patients with cachexia [25]. Only IL-6 was detected
in all patients at a concentration greater than 10pg/mL [25]. The concentration of IL-6 was
seen to gradually rise during the early stages of cachexia followed by a sharp rise in the week
prior to death [25]. It was hypothesised that circulating macrophages and T lymphocytes
produce IL-6 in response to tumour burden, or plasma IL-6 is produced by the tumour
mass itself [25,52]. IL-6 is a pro-inflammatory cytokine that regulates immune reactions to
tissue damage. There is a growing consensus that plasma IL-6 is a prognostic factor in solid
organ malignancies [53,54], however changes in plasma IL-6 levels are affected by carci-
noma type [55].
Paulsen et al. identified that a number of inflammatory cytokines were significantly elevated
in the plasma in the last months of life [46] (Table 2). Interestingly, soluble tumour necrosis
factor receptor-1 (sTNF-r1), IL-6, CRP and erythrocyte sedimentation rate (ESR) were highly
correlated with quality of life, and interleukin-1β (IL-1β) was moderately correlated with
breathlessness[46]. Further research is required to confirm these preliminary findings and
assess their prognostic significance.
There is Grade A evidence that WBC count is an independent predictor of survival in
advanced cancer [31,34,35]. In a UK multicentre cohort study, Gwilliam et al. demonstrated
WBC count and platelet count independently predicted survival at two months and two weeks
in a heterogeneous population of advanced cancer patients across a variety of palliative care
settings [34].
There is Grade A evidence that lymphopenia is an independent predictor of survival in
advanced cancer [23,31,33,34,41,43]. Gwilliam et al. confirmed that lymphocyte count was a
significant predictor of two-month but not two-week survival [34]. The mechanisms driving
lymphopenia in advanced cancer are unknown. Immunodeficiency in advanced cancer has
been well documented and there is a significant trend of decreasing functional T cell popula-
tions (including CD4, CD8, CD4:CD8 ratio and naïve T cells) with cancer progression: this is
associated with increased morbidity and mortality [56]. WBC differential rather than WBC
counts may be a more useful prognostic marker for future studies.
The prognostic role of thrombocytopaenia (Grade B) [29,34] and haemoglobin count
(Grade C) [33] has been indicated but further research is needed to confirm these findings.
Cancer anorexia-cachexia syndrome
CACS is a significant prognostic factor in advanced cancer [8] and the biological mechanisms
have been extensively studied [57,58]. There is Grade A evidence for the independent prognos-
tic role of hypoalbuminaemia in advanced cancer [19,27,33,34,41]. It is hypothesised that
hypoalbuminaemia is caused by a combination of hepatic dysfunction and CACS. Interestingly,
Gwilliam et al. demonstrated hypoalbuminaemia was a predictor of two-month but not two-
week survival, suggesting serum albumin is a predictor of dying over a longer timeframe [34].
This is contrary to the findings by Taylor et al. who demonstrated a significant change over
time and as death approached [41]. These findings highlight the need for further prospective
studies that analyse serial measurements of serum albumin at the end of life.
One article demonstrated low serum prealbumin as a significant predictor of survival in ter-
minally ill cancer patients by multivariate analysis (Grade B) [24]. Albumin and prealbumin
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levels reflect the visceral protein pool [24]. Given that prealbumin has a shorter half-life than
albumin; prealbumin may be a more sensitive marker of nutritional status [24].
Hepatic dysfunction
A number of biomarkers of liver dysfunction have been indicated as prognostic in advanced
cancer including: serum vitamin B12, albumin, bilirubin, aspartate aminotransferase (AST),
ALT, ALP, gamma-glutamyl transferase (GGT), international normalised ratio (INR), LDH
and cholesterol. The aetiology of hepatic dysfunction at the end of life is unclear. Certainly,
studies have demonstrated mixed results on the prognostic significance of liver metastasis in
advanced cancer [27,29,33,34,43].
There is Grade B evidence for the independent prognostic significance of elevated serum
vitamin B12 in advanced cancer [18]. Geissbu¨hler et al. demonstrated an inverse relationship
between survival and serum vitamin B12 levels [18]. There was also a strong correlation
between the presence of metastasis or hepatic dysfunction and an elevated serum vitamin
B12 [18]. Importantly, there was no difference in serum vitamin B12 levels in patients with
haematological malignancies (a potential confounding factor) compared to other cancers
[18]. To our knowledge no additional studies have been published that investigate vitamin
B12 as a prognostic factor.
Studies assessing serum bilirubin and other liver function tests have found mixed results.
There is Grade B evidence that hyperbilirubinaemia is an independent prognostic factor
[26,29,33,35]. Laboratory parameters ALP (Grade A), AST (Grade B) and ALT (Grade B)
proved to be prognostically significant in at least one multivariate analysis [24,34,35]. Gwilliam
et al. also found ALT predictive of two-week, but not two-month survival [34]. There are con-
flicting results whether GGT is prognostic (Grade C) [33,35]. These contrasting results may be
explained by the geographical differences in patient groups, the type of patients included and
differences in the methods of biochemical analysis of liver function tests. In contrast to serum
AST, elevations in serum ALT are rarely seen in conditions other than liver parenchymal dam-
age and may be a more sensitive marker for liver disease [24].
Prolonged INR was an independent prognostic factor by multivariate analysis in two pro-
spective studies of terminally ill cancer patients (Grade B) [26,29]. To our knowledge, no stud-
ies have been published that measure serial changes in INR and liver function tests at the end
of life.
Serum LDH is an independent prognostic factor in advanced cancer [26,29,33] (Grade B).
Suh et al. demonstrated a significant increase in LDH concentrations in the last two weeks of
life [29]. This retrospective study was limited however by sample size and was restricted to hos-
pitalised patients [29]. Prospective multicentre studies across a variety of palliative care settings
are required to confirm these preliminary findings. It has been extensively published that ele-
vated serum LDH in cancer reflects tumour burden and aggressiveness [29,59]. Serum concen-
trations can be further elevated due to hepatic necrosis caused by hepatic dysfunction and/or
metastasis in advanced cancer[29,60].
There is Grade B evidence for the prognostic role of hypocholesterolaemia in advanced can-
cer [26,29,33]. A number of risk factors for hypocholesterolaemia have been identified includ-
ing: cancer, hepatic dysfunction, CACS, haematological disease and elderly populations [61].
Renal dysfunction
A number of potential prognostic biomarkers of renal dysfunction have been indicated in
advanced cancer. Maltoni et al. demonstrated insufficient evidence for the prognostic role of
proteinuria in advanced cancer [8]. Proteinuria is prognostic in a number of solid organ
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tumours [62,63] however, to our knowledge, there have been no recent published studies that
investigate proteinuria as a predictor of survival in advanced cancer.
Elevated serum urea was demonstrated as a significant predictor of survival in three studies
by multivariate analysis (Grade A) [24,34,41]. Gwilliam et al. identified serum urea as an inde-
pendent predictor of two-week and two-month survival in advanced cancer [34]. Taylor et al.
also found that serum urea and creatinine showed a statistically and clinically significant
increase in the last two weeks of life [41]. There is Grade C evidence that serum creatinine is
prognostic in advanced cancer [26,33].
There is Grade B evidence that serum urate is a significant prognostic factor in advanced
cancer [26,29,33] and serum urate levels were significantly increased in the last two weeks of
life [26]. A number of potential explanations for raised serum urate concentrations have been
hypothesised including: renal dysfunction and cellular injury caused by hypoxia and/or
inflammation [26].
The mechanisms for renal dysfunction at the end of life are unclear. Oliguria was identified
as a significant prognostic factor in two univariate analyses [26,29]. It is hypothesised that glo-
merular filtration rate is reduced at the end of life. Although hypotension is a prognostic factor,
there are conflicting results whether blood pressure falls during the dying phase [41,64].
Electrolyte changes
There is Grade A evidence that serum sodium is a significant predictor of survival in advanced
cancer [30,35]. These studies involved hospitalised patients; and acute illness may be a con-
founding factor. One multivariate analysis identified hyponatraemia as an independent predic-
tor of survival in advanced cancer [42]. The most common aetiology of hyponatraemia in
cancer is syndrome of inappropriate secretion of antidiuretic hormone (SIADH) [42,65]. Con-
versely, hypernatraemia at the end life is commonly caused by dehydration [30] and is associ-
ated with shorter overall survival in hospitalised patients receiving palliative care [30].
Although, Taylor et al. demonstrated a statistically significant elevation in serum sodium in
the last two weeks of life, results were not clinically significant [41]. Serum sodium levels rather
than serum sodium may be a more useful prognostic factor for future studies.
The prognostic significance of hypercalcaemia has been described in a number of solid
organ and haematological malignancies including: lung [66], prostate [67], renal [68], head
and neck [69,70] and the aerodigestive tract [71]. There is conflicting evidence whether hyper-
calcaemia predicts survival in advanced cancer (Grade C). By univariate analysis, Alsirafy et al.
found that hypercalcaemia was associated with a 69% inpatient death rate in hospitalised
patients [30]. However, an additional three articles failed to demonstrate statistical significance
[27,33,40]. Contrasting results may reflect differences in study settings, tumour type, and the
presence of bony metastasis. One univariate analysis identified hypermagnesemia to be predic-
tive of survival (Grade C) in patients referred to the hospital palliative care team [30].
Although Cui et al. demonstrated serum potassium as a prognostic factor by univariate
analysis[35], an additional three articles were identified which failed to demonstrate statistical
significance including two multivariate analyses (Grade D) [30,33,41]. In one univariate analy-
sis, abnormal plasma glucose levels were predictive of survival (Grade C) [35].
Non-invasive research methodologies
Coyle et al. recently presented preliminary results of a statistically significant increase in the
number of volatile organic compounds (VOCs) in the urine in the last weeks of life using Gas
Chromatography Mass Spectrometry (GC-MS) [44]. Interestingly, the steepest rise in signifi-
cant VOCs was seen in the last week of life [44].
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Prognostic models
Based on the outcome of these studies a number of prognostic models have been developed to
assist clinicians. Simmons et al. recently reviewed the role of prognostic models in advanced
cancer [12]. They concluded that ‘various prognostic tools have been validated, but vary in
their complexity, subjectivity and therefore clinical utility’ [12].
What makes this study unique?
The Neuberger review made a number of recommendations to improve end of life care,
including research into the biology of dying [1]. This is the first study to specifically investigate
biomarkers in advanced cancer patients in the last months of life and attempts to extrapolate
which biological processes are affected. A number of common themes emerged including: sys-
temic inflammation, organ dysfunction and CACS.
What is the significance of the findings of this analysis?
This review demonstrates that there are many biological prognostic factors that have an associ-
ation with the dying process. Although this review is unable to provide evidence of causation it
is important for healthcare professionals to be aware of these prognostic factors and their
incorporation into existing prognostic models [12], which may be useful in clinical practice.
However, further research is needed to understand the application of biomarkers in prognosti-
cation at the end of life.
Identification of biomarkers of dying is an important area for future research that will lead
to both improved clinical tools for managing patients, and shed light on fundamental pro-
cesses such as the answer to the question: why do patients die from cancer?
The “terminal cancer syndrome” theory is characterised by common terminal symptoms
including dry mouth, dyspnoea, malnutrition and susceptibility to infection, which are shared
amongst heterogeneous groups patients with advanced cancer [7]. In the last three days of life,
Bruera et al. demonstrated that blood pressure and oxygen saturations decrease significantly in
cancer patients [64]. Heart rate variability [72] and autonomic dysfunction [73] have also been
described. Thus, changes in vital signs and biomarkers suggest end organ dysfunction.
In non-cancer animal models, McDonald et al. demonstrated a rapid loss of body weight
and disintegration of the circadian rhythmicity in deep body temperature several days before
death in senescent but not presenescent rats [74]. Tankersley et al. also demonstrated a pre-
dictable sequence of pathophysiological events associated with dying including a fall in daily
mean heart rate and a loss of circadian pattern in deep body temperature 3–4 weeks before
death [75]. Further, increased lung permeability, reduced lung volume and compliance were
seen during a period of terminal senescence [76].
At post-mortem, Kadhim et al. demonstrated the over-expression of interleukin-2 (IL-2) in
situ in brainstem neuronal centres implicated in autonomic control of vital homeostatic func-
tions in adults and children who died from severe illness [77,78]. It was hypothesised that bio-
logical stressors trigger over-expression of IL-2 in brainstem neuronal centres, inducing a
neurochemical cascade that results in disturbed homeostatic control of cardiorespiratory
responses, and eventual death; however, populations were confined to non-cancer diagnoses
[78]. Further, Perry et al. hypothesised that a neurochemicals including glutamate decarboxyl-
ase, tissue pH and tryptophan could reflect novel biomarkers of agonal status [79] and hence
the dying phase.
Prognostic factors and post-mortem therefore studies suggest a common biological process
to dying. Measurable parameters in the blood suggest a systemic inflammatory response
including: elevated CRP, IL-6 and other pro-inflammatory cytokines, hypoalbuminaemia,
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leucocytosis and neutrophilia. Interestingly, post-mortem studies demonstrated evidence of
silent pneumonia in advanced cancer [80,81]. Although it is not possible to assume causation,
these findings are of clinical and research interest. For example, the presence of silent pneumo-
nia, may to some extent explain why 24% of patients with terminal cancer have breathlessness
despite a lack of risk factors [7]. Further, Kontoyiannis et al. demonstrated pulmonary candidi-
asis in 21% of patients with evidence of pneumonia at post-mortem and 42% of these patients
had disseminated candidiasis [82].What is the role of immunodeficiency towards the end of life?
Is there an overarching aetiology for common terminal symptoms? Does over-expression of IL-2
in brainstem neuronal centres together with silent pneumonia, contribute to breathing changes
seen during the dying phase?When is the “point of no return” when the administration of antibi-
otics is futile? The current lack of research in these areas, together with our desire to improve
patient care, highlights the importance for further research into the biology of dying. Biomark-
ers are important adjuncts in prognostication and the recognition of dying, but equally
increase our understanding of the dying process.
Key areas for future research include: serial blood measurements of candidate biomarkers
including inflammatory cytokines during the dying phase, intracerebral measurement of cyto-
kines; and correlation with physiological parameters observed during the dying phase. Inter-
estingly, Coyle et al. recently presented a feasibility study for taking serial urine samples from
hospice inpatients towards the end of life[83] and demonstrated elevated levels of a number of
volatile VOCs in the urine during the dying phase[44]. Non-invasive research methodologies
are an important area for future research.
Limitations
There are several limitations with this review. This review only included published studies
from year 2000, in order to conduct an in-depth analysis of current studies since the Maltoni
et al. paper. The authors recognise that a systematic review of randomised controlled trials is
the gold standard in research synthesis, however within the constraints of current available evi-
dence, the PRISMA standards for reporting evidence were applied to ensure a systematic
structure to the search, selection and review of the literature [13]. However, reviewers were not
blinded to the authors, institutions, or journals of publication, which could have introduced
selection bias.
This review excluded non-cancer conditions and was limited to patient populations with a
median survival of90 days, which meant that a selected number of articles were excluded.
This was important given that “advanced cancer” is poorly defined in the literature; exclusion
of these articles did not change the overall findings of this review.
Many of the studies included in Table 2 were heterogeneous in nature, small and under-
powered, and the quality of studies varied considerably. Few studies have specifically investi-
gated changes in the last weeks of life. We screened some studies that may have contained
information specific to the objectives of this review, but data was not presented in a way that
was specific to advanced cancer. There are considerable ethical implications of conducting
research in patients in the last few weeks of life, in particular when this involves invasive proce-
dures. We recognise that this may have limited the number of studies for inclusion in this
review. Certainly, a number of included studies were limited by sample size and lack of proto-
cols for collection of blood samples.
It was not possible to provide a synthesis of the evidence due to the heterogeneity of the
sample. Despite this, the findings of this review are of particular research interest. This
review makes an important contribution to the evidence base on the biology of dying and
highlights potential areas for research funding and analysis. Attention has been given to the
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ethical and methodological implications of research into the biology of dying and future
strategies are described.
Conclusion
The biology of dying is an important area for future research interest. The evidence to date is
largely focused on signs, symptoms and prognostic factors. Despite appearances, the extent to
which cancer patients follow a common terminal trajectory is uncertain and high quality
research should be conducted to explore this concept further. This review identifies a number
common themes shared amongst advanced cancer patients and highlights candidate biomark-
ers which may be indicative of a common biological process to dying. Attention should be
placed on understanding the physiological process of dying and identification of candidate
biomarkers of imminent death. This will increase clinicians’ confidence in identifying the
dying process, inform decision making surrounding end of life care, and ensure the best possi-
ble care for patients and their families.
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